… of AGW in non‐immunocompromised adults. … for anogenital warts in non‐immunocompromised
adults Imiquimod compared to placebo for AGW in non‐immunocompromised adults …

… , included immunocompromised patients and only one RCT using CO 2 laser [64], whereas
our NMA compared 49 RCTs, focused on non-immunocompromised adults and compared 5 …

Introduction Several therapeutic options are available to manage anogenital warts (AGWs).
However, no hierarchy of treatments is provided in the latest European and American …

… Cryotherapy is one of the most commonly used therapeutic modalities to treat anogenital
warts (AGWs), but this treatment was not clearly established in the recent international …

… of HPV 6 and 11 in the UK has fallen in vaccinated groups with an associated 35% decline
in the number of genital warts … do not differ from non-immunocompromised individuals. …

… Several studies included patients with either perianal or genital warts, but clearance rates …
The Cochrane review of topical 5-FU for genital warts in non-immunocompromised individuals…

… It provides guidance for best practice in the care of patients with anogenital warts including
… 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst …

… Adults, children, pregnant women, immunocompromised or non-immunocompromised
patients were included. When the same study cohort had been used in several reviews, it was …

… In the presence of perianal warts, a proportion of patients will have warts in the anal canal.
If patients have anal … Some patients present with intraepithelial neoplastic lesions in the …

… Treatment with imiquimod followed by excision of residual lesions has been reported
with long-term clearance of anogenital warts in those patients for whom monotherapy was …